Article Sidebar
DOI:
10.4314/tjpr.v14i6.7Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Etanercept Inhibits Pro-inflammatory Cytokines Expression in Titanium Particle-Stimulated Peritoneal Macrophages
Abstract
Purpose: To investigate the inhibitory role of Etanercept in pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 production in titanium (Ti) particle stimulated macrophages.
Methods: Peritoneal macrophages were stimulated with 1 × 109 Ti particles and treated simultaneously with or without 10, 100, or 1000 ng/mL Etanercept. The levels of TNF-α, IL-1β and IL-6 in the culture supernatants were measured using ELISA.
Results: Titanium particles could stimulate TNF-α, IL-1β and IL-6 secretion in peritoneal macrophages. Etanercept inhibited Ti particle-induced TNF-α release by 29.7 % at 10 ng/ml (19.19 ± 4.72 pg/mL, p < 0.01), 49.3 % at 100 ng/mL (13.83 ± 3.72 pg/ml, p < 0.01) and 60.4 % at 1000 ng/mL (10.82 ± 3.87 pg/mL, p < 0.001), IL-1β release by 5.23 % at 10 ng/mL (34.79 ± 7.83 pg/mL, p > 0.05), 21.06 % at 100 ng/mL (28.98 ± 4.81 pg/mL, p < 0.01) and 29.83 % at 1000 ng/mL (25.76 ± 5.23 pg/ml, p < 0.001), and IL-6 release by 38.69 % at 10 ng/mL (256.8 ± 99.56 pg/mL, p < 0.01), by 42.13 % at 100 ng/mL (242.4 ± 33.26 pg/mL, p < 0.01) and 53.4 % at 1000 ng/ml (195.2 ± 48.82 pg/mL, p < 0.001).
Conclusion: Etanercept has potent ability to prevent wear debris–induced osteolysis and may be valuable as a therapeutic agent for the treatment of prosthetic loosening in humans.
Keywords: Etanercept; titanium particle; proinflammatory cytokines; peritoneal macrophages
